OpenAI’s Noam Brown notes the plateau is actually really far out these days, with a well-scaffolded GPT-5.5 able to think for weeks before benchmarks flatten. Scaffolding, not scale, buys the depth.
A lone PhD synthesized the first selective GalR1 antagonist for Alzheimer’s in a garage lab run by Claude Code and a liquid-handling robot.